NCT00005906View on ClinicalTrials.gov

Treatment With Octreotide in Patients With Lymphangioleiomyomatosis

PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

June 30, 2000

Primary Completion Date

April 30, 2008

Conditions
LymphangioleiomyomatosisLymphangiomyomasPleural EffusionsAscites
Interventions
DRUG

Octreotide

Treatment with octreotide starts at a dose of 50 micrograms(ug) twice a day which is increased to 100 ug twice a day after two weeks and to 200 ug twice a day two weeks later. After two months, if there is no response the dose shall be increased to 400 ug twice a day.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT00005906 - Treatment With Octreotide in Patients With Lymphangioleiomyomatosis | Biotech Hunter | Biotech Hunter